Short answer · Medically reviewed summary · Last updated: 2026-04-07
The estimated prevalence of Morquio Syndrome (Mucopolysaccharidosis type IV) ranges from approximately 1 in 200,000 to 1 in 300,000 live births globally, though these figures vary significantly by geography and diagnostic detection rates. Epidemiological Overview Morquio Syndrome is classified as an ultra-rare, progressive, autosomal recessive lysosomal storage disorder. Because it is autosomal recessive, it affects males and females with equal frequency.
What is the prevalence of Morquio Syndrome?
Prevalence of Morquio Syndrome: how many people are affected worldwide, differences by sex and region, with sources.
The estimated prevalence of Morquio Syndrome (Mucopolysaccharidosis type IV) ranges from approximately 1 in 200,000 to 1 in 300,000 live births globally, though these figures vary significantly by geography and diagnostic detection rates.
Epidemiological Overview
Morquio Syndrome is classified as an ultra-rare, progressive, autosomal recessive lysosomal storage disorder. Because it is autosomal recessive, it affects males and females with equal frequency. While clinical presentations often begin in early childhood—typically between the ages of one and three years—the disease is lifelong, and individuals with Morquio Syndrome continue to manage complex physical health needs into adulthood.
Geographic and Diagnostic Challenges
Incidence rates are not uniform; for instance, some reports suggest higher frequencies in certain isolated populations due to founder effects. Accurate data collection remains a significant challenge for the medical community. Many cases of Morquio Syndrome go underdiagnosed or misdiagnosed as other forms of skeletal dysplasia, especially in regions with limited access to specialized metabolic screening or enzymatic testing. Consequently, the true prevalence of Morquio Syndrome is likely higher than current clinical estimates suggest.
Real-World Perspectives
At DiseaseMaps.org, we have 57 people with Morquio Syndrome currently sharing their experiences. This community-driven data serves as a vital complement to traditional epidemiological research, helping us better understand the real-world diagnostic journeys and geographic distribution of patients living with Morquio Syndrome today. By connecting patients, we improve our collective knowledge of how this condition manifests across diverse populations.
Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- Orphanet (ORPHA:601): Mucopolysaccharidosis type IV.
- NIH Genetic and Rare Diseases Information Center (GARD): Morquio syndrome.
- OMIM (Online Mendelian Inheritance in Man): Mucopolysaccharidosis IVA (MPS4A).
